February 2021 Publications
- Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates. Sakai S, Lora NE, Kauffman KD, Dorosky DE, Oh S, Namasivayam S, Gomez F, Fleegle JD, Arlehamn CSL, Sette A, Sher A. bioRxiv. 2021 Feb 1. doi: 10.1101/2021.01.29.428844.
- The role of donor‐unrestricted T‐cells, innate lymphoid cells, and NK cells in anti‐mycobacterial immunity. Ruibal P, Voogd L, Joosten SA, Ottenhoff TH, Immunol Rev. 2021 Feb 2. doi: 10.1111/imr.12948.
- In vivo antigen expression regulates CD4 T cell differentiation and vaccine efficacy against Mycobacterium tuberculosis infection. Clemmensen HS, Dube JY, McIntosh F, Rosenkrands I, Jungersen G, Aagaard C, Andersen P, Behr MA, Mortensen R. bioRxiv. 2021 Feb 3. doi: 10.1101/2021.02.02.429488.
- The safety and efficacy of BCG encapsulated alginate particle (BEAP) against M.tb H37Rv infection in Macaca mulatta: A pilot study. Kesarwani A, Sahu P, Jain K, Sinha P, Mohan KV, Nagpal PS, Singh, S, Zaidi R, Nagarajan P, Upadhyay P. Sci. Rep. 2021 Feb 4. doi: 10.1038/s41598-021-82614-5.
- Interaction of TLR4 and TLR8 in the innate immune response against Mycobacterium tuberculosis. Thada S, Horvath GL, Müller MM, Dittrich N, Conrad ML, Sur S, Hussain A, Pelka K, Gaddam SL, Latz E, Slevogt H. Int J Mol Sci. 2021 Feb 4. doi: 10.3390/ijms22041560.
- Id3 and Bcl6 promote the development of long-term immune memory induced by tuberculosis subunit vaccine. Han J, Ma Y, Ma L, Tan D, Niu H, Bai C, Mi Y, Xie T, Lv W, Wang, J, Zhu B. Vaccines (Basel). 2021 Feb 5. doi: 10.3390/vaccines9020126.
- Bacillus Calmette-Guerin (BCG): the adroit vaccine. Adesanya OA, Uche-Orji CI, Adedeji YA, Joshua JI, Adesola AA, Chukwudike CJ. AIMS Microbiol. 2021 Feb 8. doi: 10.3934/microbiol.2021007.
- Can what we have learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine? Dockrell HM, Butkeviciute E. Vaccine. 2021 Feb 11. doi: 10.1016/j.vaccine.2021.01.068.
- Prediction and identification of CD4+ T cell epitope for the protective antigens of Mycobacterium tuberculosis. Liu J, Chen X, Wang J, Wu F, Zhang J, Dong J, Zhang H, Liu X, Hu N, Wu J, Zhang L. Medicine (Baltimore). 2021 Feb 12. doi: 10.1097/MD.0000000000024619.
- Systematic evaluation of Mycobacterium tuberculosis proteins for antigenic properties identifies Rv1485 and Rv1705c as potential protective subunit vaccine candidates. Wang Y, Li Z, Wu S, Fleming J, Li C, Zhu G, Chen B, Ren B, Wang X, Du B, Li P. Infect Immun. 2021 Feb 16. doi: 10.1128/IAI.00585-20.
- BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Prentice S, Nassanga B, Webb EL, Akello F, Kiwudhu F, Akurut H, Elliott AM, Arts RJ, Netea MG, Dockrell HM, Cose S, Delayed BCG Study Team. Lancet Infect Dis. 2021 Feb 17. doi: 10.1016/S1473-3099(20)30653-8.
- Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection. Mpande CA, Rozot V, Mosito B, Musvosvi M, Dintwe OB, Bilek N, Hatherill M, Scriba TJ, Nemes E, ACS Study Team. EBioMedicine. 2021 Feb 18. doi: 10.1016/j.ebiom.2021.103233.
- Immunologic goalposts for TB vaccine development. Um PK, Bishai WR. Cell Host Microbe. 2021 Feb 10. doi: 10.1016/j.chom.2021.01.011.
- Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination. Bitencourt J, Wilkie M, Alvarez MPP, Jacobs A, Wright D, Harris SA, Smith SG, Elias S, White A, Sharpe S, O’Shea MK. bioRxiv. 2021 Feb 18. doi: 10.1101/2021.02.18.431837.
- B-Cells and antibodies as contributors to effector immune responses in tuberculosis. Rijnink WF, Ottenhoff TH, Joosten SA. Front. Immunol. 2021 Feb 18. doi: 10.3389/fimmu.2021.640168.
- Intranasal immunization with peptide-based immunogenic complex enhances BCG vaccine efficacy in a murine model of tuberculosis. Kumar S, Bhaskar A, Patnaik G, Sharma C, Singh DK, Kaushik SR, Chaturvedi S, Das G, Dwivedi VP. JCI Insight. 2021 Feb 22. doi: 10.1172/jci.insight.145228.
- BCG vaccine protection against Mycobacterium tuberculosis infection by level of exposure in The Gambia. Campbell N, Verrall AJ, Donkor S, Sutherland JS, Hill PC. J Infect Dis. 2021 Feb 24. doi: 10.1093/infdis/jiaa411.
- Computational discovery and ex-vivo validation study of novel antigenic vaccine candidates against tuberculosis. Arega AM, Pattanaik KP, Nayak S, Mahapatra RK. Acta Tropica. 2021 Feb 24. doi: 10.1016/j.actatropica.2021.105870.
- The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. Weerasuriya CK, Harris RC, McQuaid CF, Bozzani F, Ruan Y, Li R, Li T, Rade K, Rao R, Ginsberg, AM, Gomez GB. BMC Med. 2021 Feb 26. doi: 10.1186/s12916-021-01932-7.